Abstract
In advanced biliary tract cancer (BTC), combination of cisplatin and gemcitabine is recognized as the standard first-line chemotherapy regimen. Recently, FOLFOX regimen was tested in prospective randomized trial, ABC-06, and revealed to be beneficial as second-line therapy. However, there is no available data regarding the benefit of the treatment beyond first-line in Thai patients. This study aims to evaluate the efficacy of subsequent-line therapy in Advanced BTC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
